English

TARO PHARMACEUTICAL INDUSTRIES LTD

EDGAR

TARO Report (type unavailable) · filed 2024-06-24

254 filing records in this dataset, filed from 2009-02-10 to 2024-06-24. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

145 million USD

2012 Q4 · USD

Exact inputs and evidence

Revenue: 145141000 USD Source

Operating margin

45.63%

2012 Q4 · %

Exact inputs and evidence

Operating Income: 66222000 USD Source
Revenue: 145141000 USD Source

Operating cash flow

78.1 million USD

2012 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: 78094000 USD Source

Free cash flow

76.5 million USD

2012 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: 78094000 USD Source
Capital Expenditure: 1610000 USD Source

Cash and cash equivalents: 154 million USD 2023-03-31 Source
Exact value

154495000 USD
Long-term debt including current maturities: 0 USD 2023-03-31 Source
Exact value

0 USD
Shares outstanding: 37.6 million shares 2023-03-31 Source
Exact value

37584631 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

37584631 shares · 2022-03-31· Source
37584631 shares · 2023-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-06-24.

Financial data available through: 2023-03-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2023-03-31
Operating income: 11 of 11 periods available· newest 2023-03-31
Net income: 11 of 11 periods available· newest 2023-03-31
Operating cash flow: 11 of 11 periods available· newest 2023-03-31
Capital expenditure: 11 of 11 periods available· newest 2023-03-31
Total assets: 11 of 11 periods available· newest 2023-03-31
Total liabilities: 11 of 11 periods available· newest 2023-03-31
Current assets: 11 of 11 periods available· newest 2023-03-31
Current liabilities: 11 of 11 periods available· newest 2023-03-31
Cash and cash equivalents: 11 of 11 periods available· newest 2023-03-31
Long-term debt including current maturities: 11 of 11 periods available· newest 2023-03-31
Shares outstanding: 11 of 11 periods available· newest 2023-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+2.1%

Prior period

USD 561.35 million

2021-04-01 – 2022-03-31
Current period

USD 572.95 million

2022-04-01 – 2023-03-31

Exact inputs and evidence

572952000 − 561347000 = 11605000 USD

561347000 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
572952000 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Year-over-year change in Revenue: 11605000 USD Concept: fundies:Revenue Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 572952000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#6148998 Filing: 000095017023030778 Input fundies:Revenue: 561347000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#6183515 Filing: 000095017023030778
The citation records this snapshot. The page link may show a newer release later.
Net income
-56.3%

Prior period

USD 58.27 million

2021-04-01 – 2022-03-31
Current period

USD 25.45 million

2022-04-01 – 2023-03-31

Exact inputs and evidence

25445000 − 58266000 = -32821000 USD

58266000 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
25445000 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Year-over-year change in Net income: -32821000 USD Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 25445000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#5433615 Filing: 000095017023030778 Input fundies:NetIncome: 58266000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#5440066 Filing: 000095017023030778
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 190.45 million

Prior period

−USD 158.7 million

2021-04-01 – 2022-03-31
Current period

USD 31.75 million

2022-04-01 – 2023-03-31

Exact inputs and evidence

31750000 − -158698000 = 190448000 USD

-158698000 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
31750000 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Year-over-year change in Operating cash flow: 190448000 USD Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 31750000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3663498 Filing: 000095017023030778 Input fundies:OperatingCashFlow: -158698000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3665846 Filing: 000095017023030778
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+49%

Prior period

USD 11.8 million

2021-04-01 – 2022-03-31
Current period

USD 17.58 million

2022-04-01 – 2023-03-31

Exact inputs and evidence

17577000 − 11800000 = 5777000 USD

11800000 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
17577000 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Year-over-year change in Capital expenditure: 5777000 USD Concept: fundies:CapitalExpenditure Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 17577000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3684889 Filing: 000095017023030778 Input fundies:CapitalExpenditure: 11800000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3687167 Filing: 000095017023030778
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2022-04-01 – 2023-03-31

Revenue USD 572.95 million 100% of revenue
Cost of revenue USD 304.63 million 53% of revenue
Operating expenses USD 250.61 million 44% of revenue
Operating income USD 17.71 million 3.1% of revenue
Tax, interest and other Derived −USD 7.73 million −1.3% of revenue
Net income USD 25.45 million 4.4% of revenue

Cash

Operating cash flow USD 31.75 million 5.5% of revenue
Capital expenditure USD 17.58 million 3.1% of revenue
Free cash flow Derived USD 14.17 million 2.5% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 47%9.2%43%
2015 56%39%
2016 57%35%
2017 52%41%
2018 32%14%54%
2019 42%56%
2020 38%62%
2021 Operating loss: operating costs were 175% of revenue.
2022 10%89%
2023 Net income was higher than operating income, so the split is not drawn.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2013-04-01 – 2014-03-31	759285000	329032000 Derived	430253000	69866000 Derived	360387000	336395000 Derived	Source 2013-04-01 – 2014-03-31: 759285000 USD Inspect Revenue Open source 2013-04-01 – 2014-03-31: 430253000 USD Inspect Operating Income Open source 2013-04-01 – 2014-03-31: 360387000 USD Inspect Net Income Open source 2013-04-01 – 2014-03-31: 357644000 USD Inspect Operating Cash Flow Open source 2013-04-01 – 2014-03-31: 21249000 USD Inspect Capital Expenditure Open source
2015 2014-04-01 – 2015-03-31	862944000	335313000 Derived	527631000	43374000 Derived	484257000	386791000 Derived	Source 2014-04-01 – 2015-03-31: 862944000 USD Inspect Revenue Open source 2014-04-01 – 2015-03-31: 527631000 USD Inspect Operating Income Open source 2014-04-01 – 2015-03-31: 484257000 USD Inspect Net Income Open source 2014-04-01 – 2015-03-31: 406788000 USD Inspect Operating Cash Flow Open source 2014-04-01 – 2015-03-31: 19997000 USD Inspect Capital Expenditure Open source
2016 2015-04-01 – 2016-03-31	950751000	336283000 Derived	614468000	73536000 Derived	540932000	376156000 Derived	Source 2015-04-01 – 2016-03-31: 950751000 USD Inspect Revenue Open source 2015-04-01 – 2016-03-31: 614468000 USD Inspect Operating Income Open source 2015-04-01 – 2016-03-31: 540932000 USD Inspect Net Income Open source 2015-04-01 – 2016-03-31: 395128000 USD Inspect Operating Cash Flow Open source 2015-04-01 – 2016-03-31: 18972000 USD Inspect Capital Expenditure Open source
2017 2016-04-01 – 2017-03-31	879387000	364436000 Derived	514951000	58595000 Derived	456356000	401780000 Derived	Source 2016-04-01 – 2017-03-31: 879387000 USD Inspect Revenue Open source 2016-04-01 – 2017-03-31: 514951000 USD Inspect Operating Income Open source 2016-04-01 – 2017-03-31: 456356000 USD Inspect Net Income Open source 2016-04-01 – 2017-03-31: 437535000 USD Inspect Operating Cash Flow Open source 2016-04-01 – 2017-03-31: 35755000 USD Inspect Capital Expenditure Open source
2018 2017-04-01 – 2018-03-31	661913000	358903000 Derived	303010000	91860000 Derived	211150000	296803000 Derived	Source 2017-04-01 – 2018-03-31: 661913000 USD Inspect Revenue Open source 2017-04-01 – 2018-03-31: 303010000 USD Inspect Operating Income Open source 2017-04-01 – 2018-03-31: 211150000 USD Inspect Net Income Open source 2017-04-01 – 2018-03-31: 323689000 USD Inspect Operating Cash Flow Open source 2017-04-01 – 2018-03-31: 26886000 USD Inspect Capital Expenditure Open source
2019 2018-04-01 – 2019-03-31	669893000	373700000 Derived	296193000	14416000 Derived	281777000	296717000 Derived	Source 2018-04-01 – 2019-03-31: 669893000 USD Inspect Revenue Open source 2018-04-01 – 2019-03-31: 296193000 USD Inspect Operating Income Open source 2018-04-01 – 2019-03-31: 281777000 USD Inspect Net Income Open source 2018-04-01 – 2019-03-31: 323709000 USD Inspect Operating Cash Flow Open source 2018-04-01 – 2019-03-31: 26992000 USD Inspect Capital Expenditure Open source
2020 2019-04-01 – 2020-03-31	644769000	398234000 Derived	246535000	2294000 Derived	244241000	244974000 Derived	Source 2019-04-01 – 2020-03-31: 644769000 USD Inspect Revenue Open source 2019-04-01 – 2020-03-31: 246535000 USD Inspect Operating Income Open source 2019-04-01 – 2020-03-31: 244241000 USD Inspect Net Income Open source 2019-04-01 – 2020-03-31: 271605000 USD Inspect Operating Cash Flow Open source 2019-04-01 – 2020-03-31: 26631000 USD Inspect Capital Expenditure Open source
2021 2020-04-01 – 2021-03-31	548970000	962745000 Derived	-413775000	-27122000 Derived	-386653000	28779000 Derived	Source 2020-04-01 – 2021-03-31: 548970000 USD Inspect Revenue Open source 2020-04-01 – 2021-03-31: -413775000 USD Inspect Operating Income Open source 2020-04-01 – 2021-03-31: -386653000 USD Inspect Net Income Open source 2020-04-01 – 2021-03-31: 45770000 USD Inspect Operating Cash Flow Open source 2020-04-01 – 2021-03-31: 16991000 USD Inspect Capital Expenditure Open source
2022 2021-04-01 – 2022-03-31	561347000	497888000 Derived	63459000	5193000 Derived	58266000	-170498000 Derived	Source 2021-04-01 – 2022-03-31: 561347000 USD Inspect Revenue Open source 2021-04-01 – 2022-03-31: 63459000 USD Inspect Operating Income Open source 2021-04-01 – 2022-03-31: 58266000 USD Inspect Net Income Open source 2021-04-01 – 2022-03-31: -158698000 USD Inspect Operating Cash Flow Open source 2021-04-01 – 2022-03-31: 11800000 USD Inspect Capital Expenditure Open source
2023 2022-04-01 – 2023-03-31	572952000	555238000 Derived	17714000	-7731000 Derived	25445000	14173000 Derived	Source 2022-04-01 – 2023-03-31: 572952000 USD Inspect Revenue Open source 2022-04-01 – 2023-03-31: 17714000 USD Inspect Operating Income Open source 2022-04-01 – 2023-03-31: 25445000 USD Inspect Net Income Open source 2022-04-01 – 2023-03-31: 31750000 USD Inspect Operating Cash Flow Open source 2022-04-01 – 2023-03-31: 17577000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 573M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-03-31	Revenue	759285000	Revenue: 759285000 Open source
20152015-03-31	Revenue	862944000	Revenue: 862944000 Open source
20162016-03-31	Revenue	950751000	Revenue: 950751000 Open source
20172017-03-31	Revenue	879387000	Revenue: 879387000 Open source
20182018-03-31	Revenue	661913000	Revenue: 661913000 Open source
20192019-03-31	Revenue	669893000	Revenue: 669893000 Open source
20202020-03-31	Revenue	644769000	Revenue: 644769000 Open source
20212021-03-31	Revenue	548970000	Revenue: 548970000 Open source
20222022-03-31	Revenue	561347000	Revenue: 561347000 Open source
20232023-03-31	Revenue	572952000	Revenue: 572952000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

2.1% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-03-31	Year over year	13.2%	Revenue: 759285000 Open source Revenue: 670954000 Open source
20152015-03-31	Year over year	13.7%	Revenue: 862944000 Open source Revenue: 759285000 Open source
20162016-03-31	Year over year	10.2%	Revenue: 950751000 Open source Revenue: 862944000 Open source
20172017-03-31	Year over year	-7.5%	Revenue: 879387000 Open source Revenue: 950751000 Open source
20182018-03-31	Year over year	-24.7%	Revenue: 661913000 Open source Revenue: 879387000 Open source
20192019-03-31	Year over year	1.2%	Revenue: 669893000 Open source Revenue: 661913000 Open source
20202020-03-31	Year over year	-3.8%	Revenue: 644769000 Open source Revenue: 669893000 Open source
20212021-03-31	Year over year	-14.9%	Revenue: 548970000 Open source Revenue: 644769000 Open source
20222022-03-31	Year over year	2.3%	Revenue: 561347000 Open source Revenue: 548970000 Open source
20232023-03-31	Year over year	2.1%	Revenue: 572952000 Open source Revenue: 561347000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 3.1% 2023

Net margin 4.4% 2023

Free cash flow margin 2.5% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-03-31	Operating margin	56.7%	Operating Income: 430253000 Open source Revenue: 759285000 Open source
20152015-03-31	Operating margin	61.1%	Operating Income: 527631000 Open source Revenue: 862944000 Open source
20162016-03-31	Operating margin	64.6%	Operating Income: 614468000 Open source Revenue: 950751000 Open source
20172017-03-31	Operating margin	58.6%	Operating Income: 514951000 Open source Revenue: 879387000 Open source
20182018-03-31	Operating margin	45.8%	Operating Income: 303010000 Open source Revenue: 661913000 Open source
20192019-03-31	Operating margin	44.2%	Operating Income: 296193000 Open source Revenue: 669893000 Open source
20202020-03-31	Operating margin	38.2%	Operating Income: 246535000 Open source Revenue: 644769000 Open source
20212021-03-31	Operating margin	-75.4%	Operating Income: -413775000 Open source Revenue: 548970000 Open source
20222022-03-31	Operating margin	11.3%	Operating Income: 63459000 Open source Revenue: 561347000 Open source
20232023-03-31	Operating margin	3.1%	Operating Income: 17714000 Open source Revenue: 572952000 Open source
20142014-03-31	Net margin	47.5%	Net Income: 360387000 Open source Revenue: 759285000 Open source
20152015-03-31	Net margin	56.1%	Net Income: 484257000 Open source Revenue: 862944000 Open source
20162016-03-31	Net margin	56.9%	Net Income: 540932000 Open source Revenue: 950751000 Open source
20172017-03-31	Net margin	51.9%	Net Income: 456356000 Open source Revenue: 879387000 Open source
20182018-03-31	Net margin	31.9%	Net Income: 211150000 Open source Revenue: 661913000 Open source
20192019-03-31	Net margin	42.1%	Net Income: 281777000 Open source Revenue: 669893000 Open source
20202020-03-31	Net margin	37.9%	Net Income: 244241000 Open source Revenue: 644769000 Open source
20212021-03-31	Net margin	-70.4%	Net Income: -386653000 Open source Revenue: 548970000 Open source
20222022-03-31	Net margin	10.4%	Net Income: 58266000 Open source Revenue: 561347000 Open source
20232023-03-31	Net margin	4.4%	Net Income: 25445000 Open source Revenue: 572952000 Open source
20142014-03-31	Free cash flow margin	44.3%	Revenue: 759285000 Open source Operating Cash Flow: 357644000 Open source Capital Expenditure: 21249000 Open source
20152015-03-31	Free cash flow margin	44.8%	Revenue: 862944000 Open source Operating Cash Flow: 406788000 Open source Capital Expenditure: 19997000 Open source
20162016-03-31	Free cash flow margin	39.6%	Revenue: 950751000 Open source Operating Cash Flow: 395128000 Open source Capital Expenditure: 18972000 Open source
20172017-03-31	Free cash flow margin	45.7%	Revenue: 879387000 Open source Operating Cash Flow: 437535000 Open source Capital Expenditure: 35755000 Open source
20182018-03-31	Free cash flow margin	44.8%	Revenue: 661913000 Open source Operating Cash Flow: 323689000 Open source Capital Expenditure: 26886000 Open source
20192019-03-31	Free cash flow margin	44.3%	Revenue: 669893000 Open source Operating Cash Flow: 323709000 Open source Capital Expenditure: 26992000 Open source
20202020-03-31	Free cash flow margin	38%	Revenue: 644769000 Open source Operating Cash Flow: 271605000 Open source Capital Expenditure: 26631000 Open source
20212021-03-31	Free cash flow margin	5.2%	Revenue: 548970000 Open source Operating Cash Flow: 45770000 Open source Capital Expenditure: 16991000 Open source
20222022-03-31	Free cash flow margin	-30.4%	Revenue: 561347000 Open source Operating Cash Flow: -158698000 Open source Capital Expenditure: 11800000 Open source
20232023-03-31	Free cash flow margin	2.5%	Revenue: 572952000 Open source Operating Cash Flow: 31750000 Open source Capital Expenditure: 17577000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 31.8M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-03-31	Operating cash flow	357644000	Operating Cash Flow: 357644000 Open source
20152015-03-31	Operating cash flow	406788000	Operating Cash Flow: 406788000 Open source
20162016-03-31	Operating cash flow	395128000	Operating Cash Flow: 395128000 Open source
20172017-03-31	Operating cash flow	437535000	Operating Cash Flow: 437535000 Open source
20182018-03-31	Operating cash flow	323689000	Operating Cash Flow: 323689000 Open source
20192019-03-31	Operating cash flow	323709000	Operating Cash Flow: 323709000 Open source
20202020-03-31	Operating cash flow	271605000	Operating Cash Flow: 271605000 Open source
20212021-03-31	Operating cash flow	45770000	Operating Cash Flow: 45770000 Open source
20222022-03-31	Operating cash flow	-158698000	Operating Cash Flow: -158698000 Open source
20232023-03-31	Operating cash flow	31750000	Operating Cash Flow: 31750000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 14.2M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-03-31	Free cash flow	336395000	Operating Cash Flow: 357644000 Open source Capital Expenditure: 21249000 Open source
20152015-03-31	Free cash flow	386791000	Operating Cash Flow: 406788000 Open source Capital Expenditure: 19997000 Open source
20162016-03-31	Free cash flow	376156000	Operating Cash Flow: 395128000 Open source Capital Expenditure: 18972000 Open source
20172017-03-31	Free cash flow	401780000	Operating Cash Flow: 437535000 Open source Capital Expenditure: 35755000 Open source
20182018-03-31	Free cash flow	296803000	Operating Cash Flow: 323689000 Open source Capital Expenditure: 26886000 Open source
20192019-03-31	Free cash flow	296717000	Operating Cash Flow: 323709000 Open source Capital Expenditure: 26992000 Open source
20202020-03-31	Free cash flow	244974000	Operating Cash Flow: 271605000 Open source Capital Expenditure: 26631000 Open source
20212021-03-31	Free cash flow	28779000	Operating Cash Flow: 45770000 Open source Capital Expenditure: 16991000 Open source
20222022-03-31	Free cash flow	-170498000	Operating Cash Flow: -158698000 Open source Capital Expenditure: 11800000 Open source
20232023-03-31	Free cash flow	14173000	Operating Cash Flow: 31750000 Open source Capital Expenditure: 17577000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

18.9% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-03-31	Liabilities / assets	20.5%	Total Liabilities: 263783000 Open source Total Assets: 1284376000 Open source
20152015-03-31	Liabilities / assets	18.4%	Total Liabilities: 320362000 Open source Total Assets: 1737745000 Open source
20162016-03-31	Liabilities / assets	11.5%	Total Liabilities: 250889000 Open source Total Assets: 2188033000 Open source
20172017-03-31	Liabilities / assets	9.4%	Total Liabilities: 215947000 Open source Total Assets: 2289753000 Open source
20182018-03-31	Liabilities / assets	9.2%	Total Liabilities: 222811000 Open source Total Assets: 2433210000 Open source
20192019-03-31	Liabilities / assets	10.5%	Total Liabilities: 224204000 Open source Total Assets: 2135326000 Open source
20202020-03-31	Liabilities / assets	9.9%	Total Liabilities: 231493000 Open source Total Assets: 2341252000 Open source
20212021-03-31	Liabilities / assets	29.6%	Total Liabilities: 711416000 Open source Total Assets: 2406873000 Open source
20222022-03-31	Liabilities / assets	21.4%	Total Liabilities: 464917000 Open source Total Assets: 2176362000 Open source
20232023-03-31	Liabilities / assets	18.9%	Total Liabilities: 404654000 Open source Total Assets: 2135513000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.47× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-03-31	Current assets / current liabilities	4.15×	Current Assets: 1051271000 Open source Current Liabilities: 253304000 Open source
20152015-03-31	Current assets / current liabilities	4.88×	Current Assets: 1513807000 Open source Current Liabilities: 310005000 Open source
20162016-03-31	Current assets / current liabilities	7.65×	Current Assets: 1877595000 Open source Current Liabilities: 245462000 Open source
20172017-03-31	Current assets / current liabilities	9.53×	Current Assets: 1999024000 Open source Current Liabilities: 209837000 Open source
20182018-03-31	Current assets / current liabilities	8.79×	Current Assets: 1896635000 Open source Current Liabilities: 215756000 Open source
20192019-03-31	Current assets / current liabilities	6.84×	Current Assets: 1482720000 Open source Current Liabilities: 216821000 Open source
20202020-03-31	Current assets / current liabilities	6.88×	Current Assets: 1532598000 Open source Current Liabilities: 222731000 Open source
20212021-03-31	Current assets / current liabilities	2.17×	Current Assets: 1470835000 Open source Current Liabilities: 676301000 Open source
20222022-03-31	Current assets / current liabilities	3.1×	Current Assets: 1337886000 Open source Current Liabilities: 432118000 Open source
20232023-03-31	Current assets / current liabilities	3.47×	Current Assets: 1336428000 Open source Current Liabilities: 385548000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2013-04-01 – 2014-03-31	USD 360.39 million Exact value Exact value: 360387000 USD 2013-04-01 – 2014-03-31: 360387000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2014-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 360387000 USD Concept: fundies:NetIncome Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:NetIncome: 360387000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/taro-20160331.xml#208805 Filing: 000156459016020459 The citation records this snapshot. The page link may show a newer release later.	USD 357.64 million Exact value Exact value: 357644000 USD 2013-04-01 – 2014-03-31: 357644000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2014-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 357644000 USD Concept: fundies:OperatingCashFlow Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 357644000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/taro-20160331.xml#247432 Filing: 000156459016020459 The citation records this snapshot. The page link may show a newer release later.	USD 21.25 million Exact value Exact value: 21249000 USD 2013-04-01 – 2014-03-31: 21249000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2014-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 21249000 USD Concept: fundies:CapitalExpenditure Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21249000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/taro-20160331.xml#248106 Filing: 000156459016020459 The citation records this snapshot. The page link may show a newer release later.	USD 336.4 million Calculation and evidence 357644000 − 21249000 USD Exact free cash flow: 336395000 USD 2013-04-01 – 2014-03-31: 357644000 USD · Inspect Operating Cash Flow · Source 2013-04-01 – 2014-03-31: 21249000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2014-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 336395000 USD Concept: free-cash-flow Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 357644000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/taro-20160331.xml#247432 Filing: 000156459016020459 Input fundies:CapitalExpenditure: 21249000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/taro-20160331.xml#248106 Filing: 000156459016020459 The citation records this snapshot. The page link may show a newer release later.
2015 2014-04-01 – 2015-03-31	USD 484.26 million Exact value Exact value: 484257000 USD 2014-04-01 – 2015-03-31: 484257000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2015-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 484257000 USD Concept: fundies:NetIncome Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:NetIncome: 484257000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/taro-20170331.xml#212651 Filing: 000156459017012807 The citation records this snapshot. The page link may show a newer release later.	USD 406.79 million Exact value Exact value: 406788000 USD 2014-04-01 – 2015-03-31: 406788000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2015-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 406788000 USD Concept: fundies:OperatingCashFlow Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 406788000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/taro-20170331.xml#249792 Filing: 000156459017012807 The citation records this snapshot. The page link may show a newer release later.	USD 20 million Exact value Exact value: 19997000 USD 2014-04-01 – 2015-03-31: 19997000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2015-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 19997000 USD Concept: fundies:CapitalExpenditure Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19997000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/taro-20170331.xml#250466 Filing: 000156459017012807 The citation records this snapshot. The page link may show a newer release later.	USD 386.79 million Calculation and evidence 406788000 − 19997000 USD Exact free cash flow: 386791000 USD 2014-04-01 – 2015-03-31: 406788000 USD · Inspect Operating Cash Flow · Source 2014-04-01 – 2015-03-31: 19997000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2015-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 386791000 USD Concept: free-cash-flow Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 406788000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/taro-20170331.xml#249792 Filing: 000156459017012807 Input fundies:CapitalExpenditure: 19997000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/taro-20170331.xml#250466 Filing: 000156459017012807 The citation records this snapshot. The page link may show a newer release later.
2016 2015-04-01 – 2016-03-31	USD 540.93 million Exact value Exact value: 540932000 USD 2015-04-01 – 2016-03-31: 540932000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2016-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 540932000 USD Concept: fundies:NetIncome Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:NetIncome: 540932000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/taro-20180331.xml#207855 Filing: 000156459018015952 The citation records this snapshot. The page link may show a newer release later.	USD 395.13 million Exact value Exact value: 395128000 USD 2015-04-01 – 2016-03-31: 395128000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2016-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 395128000 USD Concept: fundies:OperatingCashFlow Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 395128000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/taro-20180331.xml#241480 Filing: 000156459018015952 The citation records this snapshot. The page link may show a newer release later.	USD 18.97 million Exact value Exact value: 18972000 USD 2015-04-01 – 2016-03-31: 18972000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2016-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 18972000 USD Concept: fundies:CapitalExpenditure Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18972000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/taro-20180331.xml#242114 Filing: 000156459018015952 The citation records this snapshot. The page link may show a newer release later.	USD 376.16 million Calculation and evidence 395128000 − 18972000 USD Exact free cash flow: 376156000 USD 2015-04-01 – 2016-03-31: 395128000 USD · Inspect Operating Cash Flow · Source 2015-04-01 – 2016-03-31: 18972000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2016-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 376156000 USD Concept: free-cash-flow Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 395128000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/taro-20180331.xml#241480 Filing: 000156459018015952 Input fundies:CapitalExpenditure: 18972000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/taro-20180331.xml#242114 Filing: 000156459018015952 The citation records this snapshot. The page link may show a newer release later.
2017 2016-04-01 – 2017-03-31	USD 456.36 million Exact value Exact value: 456356000 USD 2016-04-01 – 2017-03-31: 456356000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2017-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 456356000 USD Concept: fundies:NetIncome Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:NetIncome: 456356000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/taro-20190331.xml#235203 Filing: 000156459019022978 The citation records this snapshot. The page link may show a newer release later.	USD 437.54 million Exact value Exact value: 437535000 USD 2016-04-01 – 2017-03-31: 437535000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2017-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 437535000 USD Concept: fundies:OperatingCashFlow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 437535000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/taro-20190331.xml#269387 Filing: 000156459019022978 The citation records this snapshot. The page link may show a newer release later.	USD 35.76 million Exact value Exact value: 35755000 USD 2016-04-01 – 2017-03-31: 35755000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2017-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 35755000 USD Concept: fundies:CapitalExpenditure Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 35755000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/taro-20190331.xml#270021 Filing: 000156459019022978 The citation records this snapshot. The page link may show a newer release later.	USD 401.78 million Calculation and evidence 437535000 − 35755000 USD Exact free cash flow: 401780000 USD 2016-04-01 – 2017-03-31: 437535000 USD · Inspect Operating Cash Flow · Source 2016-04-01 – 2017-03-31: 35755000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2017-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 401780000 USD Concept: free-cash-flow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 437535000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/taro-20190331.xml#269387 Filing: 000156459019022978 Input fundies:CapitalExpenditure: 35755000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/taro-20190331.xml#270021 Filing: 000156459019022978 The citation records this snapshot. The page link may show a newer release later.
2018 2017-04-01 – 2018-03-31	USD 211.15 million Exact value Exact value: 211150000 USD 2017-04-01 – 2018-03-31: 211150000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2018-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 211150000 USD Concept: fundies:NetIncome Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:NetIncome: 211150000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/taro-20f_20200331.htm#5055011 Filing: 000156459020029846 The citation records this snapshot. The page link may show a newer release later.	USD 323.69 million Exact value Exact value: 323689000 USD 2017-04-01 – 2018-03-31: 323689000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2018-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 323689000 USD Concept: fundies:OperatingCashFlow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 323689000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/taro-20f_20200331.htm#3581657 Filing: 000156459020029846 The citation records this snapshot. The page link may show a newer release later.	USD 26.89 million Exact value Exact value: 26886000 USD 2017-04-01 – 2018-03-31: 26886000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2018-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 26886000 USD Concept: fundies:CapitalExpenditure Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26886000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/taro-20f_20200331.htm#3600436 Filing: 000156459020029846 The citation records this snapshot. The page link may show a newer release later.	USD 296.8 million Calculation and evidence 323689000 − 26886000 USD Exact free cash flow: 296803000 USD 2017-04-01 – 2018-03-31: 323689000 USD · Inspect Operating Cash Flow · Source 2017-04-01 – 2018-03-31: 26886000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2018-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 296803000 USD Concept: free-cash-flow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 323689000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/taro-20f_20200331.htm#3581657 Filing: 000156459020029846 Input fundies:CapitalExpenditure: 26886000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/taro-20f_20200331.htm#3600436 Filing: 000156459020029846 The citation records this snapshot. The page link may show a newer release later.
2019 2018-04-01 – 2019-03-31	USD 281.78 million Exact value Exact value: 281777000 USD 2018-04-01 – 2019-03-31: 281777000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2019-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 281777000 USD Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:NetIncome: 281777000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459021033341/taro-20f_20210331.htm#5100343 Filing: 000156459021033341 The citation records this snapshot. The page link may show a newer release later.	USD 323.71 million Exact value Exact value: 323709000 USD 2018-04-01 – 2019-03-31: 323709000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2019-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 323709000 USD Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 323709000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459021033341/taro-20f_20210331.htm#3594141 Filing: 000156459021033341 The citation records this snapshot. The page link may show a newer release later.	USD 26.99 million Exact value Exact value: 26992000 USD 2018-04-01 – 2019-03-31: 26992000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2019-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 26992000 USD Concept: fundies:CapitalExpenditure Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26992000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459021033341/taro-20f_20210331.htm#3612947 Filing: 000156459021033341 The citation records this snapshot. The page link may show a newer release later.	USD 296.72 million Calculation and evidence 323709000 − 26992000 USD Exact free cash flow: 296717000 USD 2018-04-01 – 2019-03-31: 323709000 USD · Inspect Operating Cash Flow · Source 2018-04-01 – 2019-03-31: 26992000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2019-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 296717000 USD Concept: free-cash-flow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 323709000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459021033341/taro-20f_20210331.htm#3594141 Filing: 000156459021033341 Input fundies:CapitalExpenditure: 26992000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000156459021033341/taro-20f_20210331.htm#3612947 Filing: 000156459021033341 The citation records this snapshot. The page link may show a newer release later.
2020 2019-04-01 – 2020-03-31	USD 244.24 million Exact value Exact value: 244241000 USD 2019-04-01 – 2020-03-31: 244241000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2020-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 244241000 USD Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:NetIncome: 244241000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017022012998/taro-20220331.htm#5165956 Filing: 000095017022012998 The citation records this snapshot. The page link may show a newer release later.	USD 271.61 million Exact value Exact value: 271605000 USD 2019-04-01 – 2020-03-31: 271605000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2020-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 271605000 USD Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 271605000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017022012998/taro-20220331.htm#3417534 Filing: 000095017022012998 The citation records this snapshot. The page link may show a newer release later.	USD 26.63 million Exact value Exact value: 26631000 USD 2019-04-01 – 2020-03-31: 26631000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2020-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 26631000 USD Concept: fundies:CapitalExpenditure Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26631000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017022012998/taro-20220331.htm#3438660 Filing: 000095017022012998 The citation records this snapshot. The page link may show a newer release later.	USD 244.97 million Calculation and evidence 271605000 − 26631000 USD Exact free cash flow: 244974000 USD 2019-04-01 – 2020-03-31: 271605000 USD · Inspect Operating Cash Flow · Source 2019-04-01 – 2020-03-31: 26631000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2020-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 244974000 USD Concept: free-cash-flow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 271605000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017022012998/taro-20220331.htm#3417534 Filing: 000095017022012998 Input fundies:CapitalExpenditure: 26631000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017022012998/taro-20220331.htm#3438660 Filing: 000095017022012998 The citation records this snapshot. The page link may show a newer release later.
2021 2020-04-01 – 2021-03-31	−USD 386.65 million Exact value Exact value: -386653000 USD 2020-04-01 – 2021-03-31: -386653000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2021-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: -386653000 USD Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:NetIncome: -386653000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#5446716 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 45.77 million Exact value Exact value: 45770000 USD 2020-04-01 – 2021-03-31: 45770000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2021-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 45770000 USD Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 45770000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3668069 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 16.99 million Exact value Exact value: 16991000 USD 2020-04-01 – 2021-03-31: 16991000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2021-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 16991000 USD Concept: fundies:CapitalExpenditure Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16991000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3689445 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 28.78 million Calculation and evidence 45770000 − 16991000 USD Exact free cash flow: 28779000 USD 2020-04-01 – 2021-03-31: 45770000 USD · Inspect Operating Cash Flow · Source 2020-04-01 – 2021-03-31: 16991000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2021-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 28779000 USD Concept: free-cash-flow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 45770000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3668069 Filing: 000095017023030778 Input fundies:CapitalExpenditure: 16991000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3689445 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.
2022 2021-04-01 – 2022-03-31	USD 58.27 million Exact value Exact value: 58266000 USD 2021-04-01 – 2022-03-31: 58266000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2022-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 58266000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:NetIncome: 58266000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#5440066 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	−USD 158.7 million Exact value Exact value: -158698000 USD 2021-04-01 – 2022-03-31: -158698000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2022-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: -158698000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -158698000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3665846 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 11.8 million Exact value Exact value: 11800000 USD 2021-04-01 – 2022-03-31: 11800000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2022-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 11800000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11800000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3687167 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	−USD 170.5 million Calculation and evidence -158698000 − 11800000 USD Exact free cash flow: -170498000 USD 2021-04-01 – 2022-03-31: -158698000 USD · Inspect Operating Cash Flow · Source 2021-04-01 – 2022-03-31: 11800000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2022-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: -170498000 USD Concept: free-cash-flow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -158698000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3665846 Filing: 000095017023030778 Input fundies:CapitalExpenditure: 11800000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3687167 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.
2023 2022-04-01 – 2023-03-31	USD 25.45 million Exact value Exact value: 25445000 USD 2022-04-01 – 2023-03-31: 25445000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Net Income: 25445000 USD Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ANetIncome&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:NetIncome: 25445000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#5433615 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 31.75 million Exact value Exact value: 31750000 USD 2022-04-01 – 2023-03-31: 31750000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Operating Cash Flow: 31750000 USD Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3AOperatingCashFlow&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 31750000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3663498 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 17.58 million Exact value Exact value: 17577000 USD 2022-04-01 – 2023-03-31: 17577000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Capital Expenditure: 17577000 USD Concept: fundies:CapitalExpenditure Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338/explain?concept=fundies%3ACapitalExpenditure&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17577000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3684889 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.	USD 14.17 million Calculation and evidence 31750000 − 17577000 USD Exact free cash flow: 14173000 USD 2022-04-01 – 2023-03-31: 31750000 USD · Inspect Operating Cash Flow · Source 2022-04-01 – 2023-03-31: 17577000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TARO PHARMACEUTICAL INDUSTRIES LTD · 2023-03-31 TARO PHARMACEUTICAL INDUSTRIES LTD (edgar:906338) Free cash flow: 14173000 USD Concept: free-cash-flow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T19:45:50Z Snapshot: 125d732259530bee4c54b51b81338d71bb012e3c1d98068fa9af79c74676eed7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/906338?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 31750000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3663498 Filing: 000095017023030778 Input fundies:CapitalExpenditure: 17577000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/906338/000095017023030778/taro-20230331.htm#3684889 Filing: 000095017023030778 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

254 filings · 1,026 latest values · 1,026 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000906338, 906338, TARO, edgar:906338

Also known as TARO PHARMACEUTICAL INDUSTRIES LTD

TARO PHARMACEUTICAL INDUSTRIES LTD

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2022-04-01 – 2023-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation